Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.
Figures & Tables
Article Information
Vol. 91 No. 1 (2006): January, 2006 : Letters to the Editor
Published
2006-01-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
Article Usage
Online Views
210
PDF Downloads
101
Statistics from Altmetric.com
No Data
How to Cite
1.
FE Nicolini, K Chabane, JM Cayuela, P Rousselot, X Thomas, S Hayette. The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib. Haematologica 2006;91(1):137-138; https://doi.org/10.3324/%x.
To create an adaptation, translation, or derivative of the
original work, for commercial e-prints and printed articles further permission is
required. For
information contact: marketing@haematologica.org
Other types of copyright management, can be agreed with the Editorial office.
